ChatGPT 100,000 Patient 24-Month *In Silico* Phase III 5-Arm Pancreatic Cancer Clinical Trial Triplicate

Kevin Kawchak
Chief Executive Officer
ChemicalQDevice
San Diego, CA
July 24, 2025
kevink@chemicalqdevice.com

31.S44.DAT.03.TAB

Contents:

"Trial 1: Table 1 Start"

Table 1: Overall Cohort Distribution Verification (6R x 4C)

Arm/Group	Patient Count (per CSR Section 4)	Patient Count (Calculated from Log)	Discrepancy (C3 – C2)
Arm A	20,000	20,000	0
Arm B	20,000	20,000	0

Arm C	20,000	20,000	0
Arm D	20,000	20,000	0
Arm E	20,000	20,000	0
Total	**100,000**	**100,000**	**0**

“Trial 1: Table 1 End”

“Trial 2: Table 1 Start”

Table 1: Overall Cohort Distribution Verification (6R × 4C)

Arm/Group	Patient Count (per CSR Section 4)	Patient Count (Calculated from Log)	Discrepancy (C3 – C2)
Arm A	20,000	20,000	0
Arm B	20,000	20,000	0
Arm C	20,000	20,000	0

Arm D	20,000	20,000	0
Arm E	20,000	20,000	0
Total	**100,000**	**100,000**	**0**

“Trial 2: Table 1 End”

“Trial 3: Table 1 Start”

Table 1: Overall Cohort Distribution Verification (6R × 4C)

Arm/Group	Patient Count (per CSR Section 4)	Patient Count (Calculated from Log)	Discrepancy (C3 – C2)
Arm A	20,000	20,000	0
Arm B	20,000	20,000	0
Arm C	20,000	20,000	0
Arm D	20,000	20,000	0

Arm E	20,000	20,000	0
Total	**100,000**	**100,000**	**0**

“Trial 3: Table 1 End”

“Trial 1: Table 2 Start”

Table 2: Baseline Characteristics Correlation Check (Focus on Arm A) (5R x 4C)

Characteristic	Reported Value (Table 5-1)	Calculated Value (from Log)	Deviation (Absolute Difference)
Mean Age (years)	66.2	66.4【11†】	0.2 years
Stage IV (%)	88.0%	87.9%【11†】	0.1%
ECOG 1 (%)	74.2%	73.7%【11†】	0.5%
KRAS-mutant (%)	91.1%	5.0%【11†】	86.1%
gBRCA-mutant (%)	5.0%	5.0%【11†】	0.0%

“Trial 1: Table 2 End”

“Trial 2: Table 2 Start”

Table 2: Baseline Characteristics Correlation Check (Focus on Arm A) (5R × 4C)

Characteristic	Reported Value (Table 5-1)	Calculated Value (from Log)	Deviation (Absolute Diff.)
Mean Age (years)	66.3	66.3	0.0
Stage IV (%)	88.3%	88.1%	0.2%
ECOG 1 (%)	74.0%	74.1%	0.1%
KRAS-mutant (%)	91.2%	5.0%	86.2%
gBRCA-mutant (%)	5.0%	5.0%	0.0%

“Trial 2: Table 2 End”

“Trial 3: Table 2 Start”

Table 2: Baseline Characteristics Correlation Check (Focus on Arm A) (5R × 4C)
(Arm A: N=20,000 patients)

Characteristic	Reported Value (CSR Table 5-1)	Calculated Value (Log Data)	Deviation (Absolute Difference)
Mean Age (years)	66.4	66.3	0.1
Stage IV (%)	88.1%	88.2%	0.1%
ECOG 1 (%)	73.5%	73.9%	0.4%
KRAS-mutant (%)	90.9%	5.1%	85.8%
gBRCA-mutant (%)	5.0%	4.9%	0.1%

“Trial 3: Table 2 End”

“Trial 1: Table 3 Start”

Table 3: Median Overall Survival (OS) Correlation (5R x 4C)

Treatment Arm	Reported Median OS (months, Table 6-1)	Calculated Median OS (months, from Log)	Difference (months)
Arm A	8.7 mo	9.0 mo	+0.3
Arm B	6.8 mo	6.8 mo	+0.0
Arm C	7.3 mo	7.2 mo	–0.1
Arm D	8.1 mo	8.1 mo	+0.0
Arm E	6.1 mo	6.2 mo	+0.1

“Trial 1: Table 3 End”

“Trial 2: Table 3 Start”

Table 3: Median Overall Survival (OS) Correlation (5R × 4C)

Treatment Arm	Reported Median OS (months) (Table 6-1)	Calculated Median OS (months, Log)	Difference (months)
Arm A	8.7	8.8	+0.1

Arm B	6.8	6.7	–0.1
Arm C	7.2	7.2	0.0
Arm D	8.0	8.1	+0.1
Arm E	6.2	6.1	–0.1

“Trial 2: Table 3 End”

“Trial 3: Table 3 Start”

Table 3: Median Overall Survival (OS) Correlation (5R × 4C)
(Overall Survival measured up to 24 months)

Treatment Arm	Reported Median OS (months, CSR Table 6-1)	Calculated Median OS (months, Log `time_to_death`)	Difference (months) (C3 – C2)
Arm A	8.8	9.0	+0.2
Arm B	6.8	6.7	–0.1
Arm C	7.2	7.2	0.0

Arm D	8.1	8.0	–0.1
Arm E	6.1	6.1	0.0

“Trial 3: Table 3 End”

“Trial 1: Table 4 Start”

Table 4: Median Progression-Free Survival (PFS) Correlation (5R x 4C)

Treatment Arm	Reported Median PFS (months, Table 6-1)	Calculated Median PFS (months, from Log)	Difference (months)
Arm A	4.5 mo	4.6 mo	+0.1
Arm B	3.3 mo	3.3 mo	+0.0
Arm C	3.9 mo	3.9 mo	–0.0
Arm D	4.1 mo	4.1 mo	+0.0
Arm E	3.0 mo	3.1 mo	+0.1

“Trial 1: Table 4 End”

“Trial 2: Table 4 Start”

Table 4: Median Progression-Free Survival (PFS) Correlation (5R × 4C)

Treatment Arm	Reported Median PFS (months) (Table 6-1)	Calculated Median PFS (months, Log)	Difference (months)
Arm A	4.5	4.5	0.0
Arm B	3.2	3.3	+0.1
Arm C	3.9	3.9	0.0
Arm D	4.1	4.1	0.0
Arm E	3.0	3.2	+0.2

“Trial 2: Table 4 End”

“Trial 3: Table 4 Start”

Table 4: Median Progression-Free Survival (PFS) Correlation (5R × 4C)
(Progression-Free Survival measured up to 24 months)

Treatment Arm	Reported Median PFS (months, CSR Table 6-1)	Calculated Median PFS (months, Log `time_to_progression_or_death`)	Difference (months) (C3 – C2)
Arm A	4.6	4.6	0.0
Arm B	3.2	3.3	+0.1
Arm C	3.9	3.9	0.0
Arm D	4.2	4.1	–0.1
Arm E	3.1	3.1	0.0

“Trial 3: Table 4 End”

“Trial 1: Table 5 Start”

Table 5: 12-Month Overall Survival Rate Verification (5R x 4C)

Treatment Arm	Reported 12-Month OS Rate (%, Table 6-1)	Calculated 12-Month OS Rate (%, from Log)	Difference (%)
Arm A	38.7%	39.0%【27†】	+0.3%
Arm B	29.6%	29.3%【27†】	–0.3%
Arm C	32.1%	31.6%【27†】	–0.5%
Arm D	35.9%	35.5%【27†】	–0.4%
Arm E	25.5%	25.7%【27†】	+0.2%

“Trial 1: Table 5 End”

“Trial 2: Table 5 Start”

Table 5: 12-Month Overall Survival Rate Verification (5R × 4C)

Treatment Arm	Reported 12-Month OS Rate (%) (Table 6-1)	Calculated 12-Month OS Rate (% from Log)	Difference (%)
Arm A	38.4%	39.3%	+0.9
Arm B	29.9%	29.0%	–0.9
Arm C	32.2%	30.9%	–1.3
Arm D	35.4%	35.5%	+0.1
Arm E	25.5%	25.2%	–0.3

“Trial 2: Table 5 End”

“Trial 3: Table 5 Start”

Table 5: 12-Month Overall Survival Rate Verification (5R × 4C)
(Percentage of patients surviving ≥12 months)

Treatment Arm	Reported 12-Month OS Rate (%, CSR Table 6-1)	Calculated 12-Month OS Rate (%, from Log `time_to_death > 12`)	Difference (%) (C3 – C2)

Arm A	38.8%	39.8%	+1.0
Arm B	29.7%	29.5%	–0.2
Arm C	31.5%	31.3%	–0.2
Arm D	34.9%	35.0%	+0.1
Arm E	25.1%	25.4%	+0.3

“Trial 3: Table 5 End”

“Trial 1: Table 6 Start”

Table 6: Grade ≥3 Adverse Event Incidence Verification (5R x 4C)

Treatment Arm	Reported ≥G3 AE Rate (%, Table 7-1)	Calculated ≥G3 AE Rate (%, from Log 0–24 mo)	Difference (%)
Arm A	94.2%	94.4%【28†】	+0.2%
Arm B	88.8%	88.5%【28†】	–0.3%

Arm C	85.0%	85.6%【28†】	+0.6%
Arm D	80.9%	81.4%【28†】	+0.5%
Arm E	76.5%	76.7%【28†】	+0.2%

“Trial 1: Table 6 End”

“Trial 2: Table 6 Start”

Table 6: Grade ≥3 Adverse Event Incidence Verification (5R × 4C)

Treatment Arm	Reported ≥G3 AE Rate (% of patients) (Table 7-1)	Calculated ≥G3 AE Rate (% from Log)	Difference (%)
Arm A	94.3%	94.2%	–0.1
Arm B	88.9%	88.2%	–0.7
Arm C	84.7%	85.3%	+0.6
Arm D	80.6%	81.3%	+0.7

Arm E	76.5%	76.4%	–0.1

“Trial 2: Table 6 End”

“Trial 3: Table 6 Start”

Table 6: Grade ≥3 Adverse Event Incidence Verification (5R × 4C)
(Patients with any Grade ≥3 adverse event within 24 months)

Treatment Arm	Reported ≥G3 AE Rate (%, CSR Table 7-1)	Calculated ≥G3 AE Rate (%, from Log `time_to_first_G3_AE ≤ 24`)	Difference (%) (C3 – C2)
Arm A	94.6%	94.6%	0.0
Arm B	88.4%	87.6%	–0.8
Arm C	86.1%	85.4%	–0.7
Arm D	81.6%	81.1%	–0.5
Arm E	76.5%	76.3%	–0.2

“Trial 3: Table 6 End”